Aurilene Gomes Cajado

Aurilene Gomes Cajado

Auto-generated profile, based on publicly available information

Aurilene Gomes Cajado

Drug Research and Development Center Department of Physiology and Pharmacology Faculty of Medicine Federal University of Ceará Fortaleza Brazil

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2024 in Mucosal Immunology
Verified
Journal Article
Open access
RNRenata R. Nascimento
Renata R. Nascimento
CACristhyane C. Aquino
Cristhyane C. Aquino
JSJosé K. Sousa
José K. Sousa
KGKalinne L. Gadelha
Kalinne L. Gadelha
ACAurilene G. Cajado
Aurilene G. Cajado
MVMariana Lima Vale
Mariana Lima Vale
Studies have reported the occurrence of gastrointestinal (GI) symptoms, primarily diarrhea in COVID-19. However, the pathobiology regarding COVID-19 in the GI tract remains limited. This work aimed to evaluate SARS-CoV-2 Spike protein interaction with gut lumen in different experimental approaches. Here, we present a novel experimental model with the inoculation of viral protein in the murine jejunal lumen, in vitro approach with human enterocytes and molecular docking analysis. Spike protein led to increased intestinal fluid accompanied by Cl- secretion, followed by intestinal edema, leukocyte infiltration, reduced glutathione levels, and increased cytokine levels (IL-6, TNF-α, IL-1β, IL-10), indicating inflammation. Additionally, the viral epitope caused disruption in the mucosal histoarchitecture with impairment in Paneth and goblet cells, including decreased lysozyme and mucin, respectively. Upregulation of TLR2 and TLR4 gene expression suggested potential activation of local innate immunity. Moreover, this experimental model exhibited reduced contractile responses in jejunal smooth muscle. In barrier function, there was a decrease in transepithelial electrical resistance and alterations in the expression of tight junction proteins in the murine jejunal epithelium. Additionally, paracellular intestinal permeability increased in human enterocytes. Finally, in silico data revealed that the Spike protein interacts with CFTR and CaCC, inferring its role in the secretory effect. Taken together, all the events observed point gut impairment, affecting the mucosal barrier to the innermost layers, establishing a successful experimental model for studying COVID-19 in the GI context.

28 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
LPLuiza Darla Aguiar Silva Paiva
Luiza Darla Aguiar Silva Paiva
ATAna Carolina Filgueiras Teles
Ana Carolina Filgueiras Teles
JSJeferson dos Santos Souza
Jeferson dos Santos Souza
POPedro Ruan Amorim Oliveira
Pedro Ruan Amorim Oliveira
BSBIANCA ELEN SOUZA
BIANCA ELEN SOUZA
Deysi WongDeysi Wong
Deysi Wong
Background/Objectives: Inflammatory breast carcinoma (IBC) is an aggressive and rare neoplasm, accounting for 1–5% of all breast cancers. Toll-like receptor type 4 (TLR4) and Advanced Glycation End Products Receptor (AGER/RAGE) have been implicated in breast cancer, and have been shown to promote tumor growth, metastasis, and resistance to therapy by modulating the tumor microenvironment and inflammatory pathways. However, the role of TLR4 and AGER in IBC has not been elucidated. Methods: TLR4 and AGER immunofluorescence expression were evaluated in 27 IBC and 24 non-IBC samples. The expression data and clinicopathological parameters, including the prognostic values of these biomarkers, were compared. TLR4 and AGER gene expression were investigated using the microarray transcriptomic dataset of IBC and non-IBC samples (Gene Expression Omnibus repository—GEO). Results: IBC samples showed higher TLR4 and AGER immunoexpression than the non-IBC group and were associated with obesity and Ki-67 expression (p < 0.05). AGER expression in IBC versus non-IBC was also statistically associated with triple-negative molecular subtypes. Non-IBC subjects with AGER immunoexpression above the cutoff (106.1%, sensitivity of 92.3%, and specificity of 56.2%) showed reduced metastasis-free survival (p = 0.032). In the multivariate analysis, high TLR4 immunostaining increased the risk of metastasis-free survival by 1.029-fold. Analyzing three external GEO datasets confirmed that TLR4 and AGER expression increased in IBC compared to non-IBC samples. Conclusions: Overall, IBC samples showed higher TLR4 and AGER expressions than other breast cancer types, shedding light on the significance of these markers on IBC biology.

15 September 2025 in European Journal of Pharmacology
Verified
Journal Article
Closed access
ACAurilene Gomes Cajado
Aurilene Gomes Cajado
MLMarina Helena Lopes
Marina Helena Lopes
GRGisele Fátima Pinheiro Rangel
Gisele Fátima Pinheiro Rangel
KFKayanny Queiroz Ferreira
Kayanny Queiroz Ferreira
CQCelia Choquenaira Quispe
Celia Choquenaira Quispe
Deysi WongDeysi Wong
Deysi Wong

4 December 2025 in European Journal of Oral Sciences
Verified
Journal Article
Open access
LRLiviane Maria Alves Rabelo
Liviane Maria Alves Rabelo
MGMariana Vasconcelos Guimarães
Mariana Vasconcelos Guimarães
ACAurilene Gomes Cajado
Aurilene Gomes Cajado
JLJosé Vitor Mota Lemos
José Vitor Mota Lemos
FSFelipe Domingos de Sousa
Felipe Domingos de Sousa
Roberto Lima-JúniorRoberto Lima-Júnior
Roberto Lima-Júnior
This study investigated how chronic metformin administration modulates the cellular profile and inflammatory markers in a zoledronic acid‐based rat model of medication‐related osteonecrosis of the jaw (MRONJ). Male Wistar rats were allocated to different treatments: (i) naïve, (ii) MRONJ (zoledronic acid, 0.2 mg/kg, i.v. on days 0, 7, 14, and 49), or (iii) MRONJ + metformin (250 mg/kg, by gavage, daily for 70 days). All rats had the inferior first molar extracted on day 42. Mandibular arches were harvested for analyzing their gums on day 70. Additionally, RAW 264.7 cells were incubated with zoledronic acid or metformin for cell viability tests and analysis of interleukin‐1β (IL‐1β) production. MRONJ was characterized by increased numbers of empty osteocyte lacunae, osteoclasts, and apoptotic osteoclasts, and by high expression of tartrate‐resistant acid phosphatase (TRAP) and F4/80 (a macrophage marker). Zoledronic acid‐incubated RAW 264.7 macrophages showed increased IL‐1β expression. Metformin reduced the number of empty bone lacunae, apoptotic osteoclasts, leukocyte infiltrate, and F4/80 positive cells in the alveolar bone. It increased TRAP expression levels without altering the number of osteoclasts. Metformin also reduced the myeloperoxidase activity and decreased IL‐1β levels in vitro. In conclusion, metformin reduced the severity of MRONJ by mitigating the inflammatory response.